Does CJC-1295 ipamorelin work? The honest answer is that the two peptides can activate the growth-hormone axis separately, but no published clinical trial has tested the combination itself. CJC-1295 increased growth hormone (GH) and insulin-like growth factor 1 (IGF-1) in a small healthy-adult study. Ipamorelin triggered a short GH pulse in healthy men, then failed the main outcome in a later surgical trial. Those findings show biological activity. They do not prove that the blend reliably changes sleep, recovery, muscle, body fat or how someone feels.
What “working” would need to mean
The phrase hides three different endpoints. The first is receptor activity: did the pituitary release more GH after exposure? The second is downstream signaling: did IGF-1 move from a measured baseline? The third is a clinical outcome: did a defined measure such as body composition, function or sleep change over time?
Only the first two have direct human evidence for either component, and even that evidence comes from separate studies. A higher hormone value cannot be converted automatically into a visible result. The rationale for pairing the peptides is explained in CJC-1295 and ipamorelin; this page stays with what the studies actually measured.
A sound evidence verdict keeps the studied formulation, route, population and endpoint attached to every number. Data from healthy adults given long-acting CJC-1295 do not establish what a shorter-acting formulation paired with a second peptide will do. An intravenous experiment in men can confirm GH release without predicting months of subcutaneous treatment. A surgical inpatient trial can answer a gut-recovery question without answering one about sleep. These are not technical footnotes; they set the boundaries of what can be claimed. With no trial of the actual blend, an individual response has to be measured rather than presumed.
Does CJC-1295 ipamorelin work in human studies?
No human study has administered CJC-1295 and ipamorelin together and measured an outcome. The evidence record is therefore a bridge built from two separate sets of data:
| Evidence | What researchers found | What it cannot establish |
|---|---|---|
| CJC-1295, Teichman 2006 | In two randomized, placebo-controlled dose-escalation studies of healthy adults ages 21–61, one injection raised mean GH 2- to 10-fold for at least 6 days and mean IGF-1 1.5- to 3-fold for 9–11 days | The study measured hormones and short-term tolerability, not body composition, recovery or sleep; it also studied long-acting CJC-1295 with DAC |
| Ipamorelin, Gobburu 1999 | Across five intravenous dose levels in 40 healthy men, ipamorelin produced one GH-release episode that peaked at 0.67 hours; its terminal half-life was 2 hours | This was a single-exposure pharmacology study, not a test of sustained clinical benefit |
| Ipamorelin, Beck 2014 | In 114 bowel-resection patients, median time to a tolerated meal was 25.3 hours with ipamorelin and 32.6 hours with placebo, a difference that was not statistically significant (P=0.15) | It did not meet the primary endpoint and does not answer questions about outpatient wellness goals |
| The combination | No clinical trial | Synergy, long-term safety and patient-important outcomes remain untested |
The 2006 CJC-1295 study in The Journal of Clinical Endocrinology & Metabolism is the source of the large hormone numbers. It examined the DAC-linked molecule, with an estimated half-life of 5.8–8.1 days. That distinction matters because CJC-1295 without DAC is a shorter-acting formulation and cannot inherit those duration numbers by name alone.
Ipamorelin's starting evidence is even narrower. The 1998 Raun experiments described selective GH release without a significant ACTH or cortisol rise even at more than 200 times the effective GH dose—but those results came from rats and pigs, not people. In the 1999 healthy-volunteer study, the measured human result was a brief GH pulse with substantial person-to-person variation.
What happened in the ipamorelin clinical program
Ipamorelin later entered phase 2 testing for postoperative ileus, the temporary gut slowdown after abdominal surgery. That program tested a medical outcome rather than a hormone marker, but it was unrelated to sleep, body composition or recovery from exercise.
The published randomized trial enrolled 117 patients and analyzed 114. The primary endpoint did not reach statistical significance: 25.3 hours to a tolerated meal with ipamorelin versus 32.6 with placebo (P=0.15). Treatment-emergent adverse events occurred in 87.5% and 94.8%, respectively, in a population already recovering from bowel surgery. Clinical development for that indication did not continue after the phase 2 program.
That negative result does not show that ipamorelin cannot release GH; the human pharmacology study already showed it can. It shows why a mechanism and a clinical benefit are different claims. Does sermorelin work? reviews a single-peptide alternative with its own small human evidence base rather than borrowing conclusions across compounds.
How long a measurable response might take
The component studies offer clocks for lab activity, not a results calendar for the blend. Intravenous ipamorelin produced a GH peak at about 40 minutes in the 1999 study, followed by an exponential decline. The long-acting DAC form of CJC-1295 raised mean IGF-1 for 9–11 days after one exposure and kept the mean above baseline for up to 28 days after repeated study exposures. Neither finding sets the timing for a no-DAC combination prescription.
If the growth-hormone axis responds, a clinician may see IGF-1 change from baseline over weeks. IGF-1 is steadier than GH, but it still must be interpreted against age-adjusted ranges, health history and the laboratory method. One random GH result is difficult to read because GH secretion is episodic. Endocrine Society guidance likewise treats GH and IGF-1 testing as contextual rather than self-explanatory.
A useful plan defines the target before treatment and repeats the same objective measure consistently. An IGF-1 rise shows that downstream signaling changed; it does not, by itself, show that strength, body composition or sleep improved. The prescriber sets the actual protocol and monitoring plan. CJC-1295 ipamorelin dosage covers how those decisions are made without turning research regimens into instructions.
What the evidence supports—and what it does not
The strongest defensible expectation is a possible biochemical response in someone whose pituitary can respond. The size and timing cannot be predicted from the combination literature because that literature does not exist. Claims of a fixed week for deeper sleep, faster recovery, added muscle or reduced fat go beyond the published trials.
Long-term safety is also uncertain. As of September 2026, the FDA's bulk-substance risk page identifies limited clinical information for CJC-1295 and limited safety information for relevant ipamorelin routes, including potential peptide impurity and immune-response concerns. This is a statement about the evidence and compounding framework, not a clinical verdict for an individual.
Through Promise, CJC-1295 / ipamorelin is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. A licensed provider may still prescribe a compounded formulation when they judge it appropriate; that decision is between the patient and the doctor.
What a useful decision looks like
A reasonable assessment starts with a documented baseline, a specific goal and an agreed stopping point if objective measures do not move. It separates an early lab change from a later clinical outcome and does not treat a sensation as proof. Persistently unchanged IGF-1, an out-of-range result, new symptoms or no movement in the chosen outcome can all change the plan.
At Promise, a licensed provider reviews every request and prescribes only when CJC-1295 / ipamorelin is medically appropriate; not everyone qualifies. If prescribed, the provider defines the endpoint, chooses the labs and decides whether the measured response justifies continuing.